Arthur G. Cook is Principal, ZS Associates.

Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...

LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...

A cGMP-related CRL can delay approval despite substantial efficacy/safety evidence and often requires manufacturing remediation and reinspection rather than additional clinical trials. Phase III CARES ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...

It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Approval was supported by IRAKLIA Phase III non-inferiority data comparing on-body injector subcutaneous isatuximab to weight-based IV, both combined with pomalidomide and dexamethasone in R/R myeloma ...

In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...

The collaboration is positioned as a translational bridge for researchers and entrepreneurs, offering an end-to-end discovery ...

Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...